By Colin Kellaher

Merck & Co. (MRK) on Wednesday said the European Commission approved the company's cancer drug Keytruda in combination with Pfizer Inc.'s (PFE) Inlyta for the first-line treatment of patients with advanced renal cell carcinoma, the most common type of kidney cancer.

The Kenilworth, N.J., drug maker said the approval includes patients in all IMDC risk groups.

The European Medicines Agency's Committee for Medicinal Products for Human Use in July recommended EC approval of the combination, which received clearance from the U.S. Food and Drug Administration in April.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 04, 2019 07:13 ET (11:13 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Merck Charts.